Skip to main content
GutCited

Fructooligosaccharides (FOS) for Chronic Constipation

C Some Evidence Limited evidence from small studies, but some positive signals exist.

Some studies show increased stool frequency. Bifidogenic effect well-established but clinical laxation effect more modest than inulin.

C

The Bottom Line

Some studies show increased stool frequency. Bifidogenic effect well-established but clinical laxation effect more modest than inulin.

Key Study Findings

Randomized Controlled Trial Double-blind
Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium.
Dose: 6 g vs: Placebo Outcome: Constipation symptoms

Population: Constipation patients

Other
Maternal or post-weaning dietary fructo-oligosaccharide supplementation reduces stillbirth rate of sows and diarrhea of weaned …
Dose: 2 g Outcome: Constipation symptoms P < 0.05

Population: Constipation patients

Randomized Controlled Trial 4.0 weeks Double-blind
Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable …
Dose: 44 g vs: Placebo Outcome: Rectal sensitivity, IBS symptoms, fecal microbiota

Population: IBS patients with rectal hypersensitivity

Randomized Controlled Trial n=64 26 weeks
Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized …
Dose: synbiotic (Lactobacillus + Bifidobacterium + 6g FOS) vs: nutritional treatment + placebo (maltodextrin) Outcome: reduction in GI symptom incidence 0.01 (nausea), 0.01 (diarrhea)

Population: HIV-infected adults on antiretroviral therapy

Randomized Controlled Trial n=84 18 weeks Double-blind
Maternal Prebiotic Ingestion Increased the Number of Fecal Bifidobacteria in Pregnant Women but Not in …
Dose: 8 g/day fructooligosaccharides vs: sucrose placebo Outcome: fecal bifidobacteria count Effect: 2.7e10 vs 1.1e10 per gram at 36 weeks <0.05

Population: Pregnant women from 26th week of gestation

Randomized Controlled Trial n=20 6 weeks Double-blind
Effects of Fructo-Oligosaccharide Supplementation on Constipation in Elderly Continuous Ambulatory Peritoneal Dialysis Patients.
Dose: 15 g/day fructo-oligosaccharides vs: placebo (maltodextrin) Outcome: constipation severity and bowel function Effect: significant improvement in constipation <0.05

Population: Elderly CAPD patients with constipation

Key Statistics

4

Studies

350

Participants

↑

Positive

C

Grade

Referenced Papers

Journal of Parkinson's … 2024 4 citations
Journal of physiology … 2009 312 citations
Journal of the … 2007 84 citations
BioFactors (Oxford, England) 2004 48 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

General:
2-10 g/day
Prebiotic Effect:
5-8 g/day for bifidogenic effect
Constipation Support:
5-10 g/day

Upper limit: Well-tolerated up to 20 g/day; start low to avoid excess gas

Dosages Studied in Research

Dosage Duration Effect N
6 g -- Positive --
2 g -- Neutral --
44 g 4.0 weeks Positive --
synbiotic (Lactobacillus + Bifidobacterium + 6g FOS) 26 weeks Positive 64
8 g/day fructooligosaccharides 18 weeks Positive 84
15 g/day fructo-oligosaccharides 6 weeks Positive 20
3 ml 4.0 weeks Positive --
15 g/d -- Mixed --

Best taken: With meals; divide doses throughout the day

Safety & Side Effects

Reported Side Effects

  • ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
  • ⚠ Abdominal cramping at higher doses
  • ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
  • ⚠ Loose stools at excessive doses

Known Interactions

  • ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
  • ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
  • ● Calcium supplements (FOS may enhance calcium absorption)

Tolerable upper intake: Well-tolerated up to 20 g/day; start low to avoid excess gas

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Fructooligosaccharides (FOS) help with Chronic Constipation?
Based on 4 studies with 350 participants, there is limited but promising evidence that Fructooligosaccharides (FOS) may support Chronic Constipation management. Our evidence grade is C (Some Evidence).
How much Fructooligosaccharides (FOS) should I take for Chronic Constipation?
Studies have used various dosages. A commonly studied range is 2-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Fructooligosaccharides (FOS)?
Reported side effects may include Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day), Abdominal cramping at higher doses, May worsen IBS symptoms in FODMAP-sensitive individuals, Loose stools at excessive doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Fructooligosaccharides (FOS) and Chronic Constipation?
We rate the evidence as Grade C (Some Evidence). This rating is based on 4 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.

Other ingredients for Chronic Constipation

Fructooligosaccharides (FOS) for other conditions

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

References

  1. [1] Cinara Regina A V Monteiro et al.. Nutrients. 2026. Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions. doi:10.3390/nu18030372 PubMed
  2. [2] Meina Li et al.. J Nutr Health Aging. 2025. Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with Functional Constipation: A Randomized, Double-Blind, … doi:10.1016/j.jnha.2025.100598 PubMed
  3. [3] Wanya Yi et al.. Food Sci Nutr. 2024. Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium. doi:10.1002/fsn3.3827 PubMed
  4. [4] Hongmin Zhen et al.. Foods. 2024. Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. doi:10.3390/foods13243993 PubMed
  5. [5] Jia Wei Hor et al.. J Parkinsons Dis. 2024. Advice to People with Parkinson's in My Clinic: Probiotics and Prebiotics. doi:10.3233/JPD-240172 PubMed
  6. [6] Kaidi Ma et al.. Anim Nutr. 2024. Maternal or post-weaning dietary fructo-oligosaccharide supplementation reduces stillbirth rate of sows and diarrhea of weaned piglets. doi:10.1016/j.aninu.2024.04.002 PubMed
  7. [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
  8. [8] Qi Zhang et al.. Front Nutr. 2022. In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota. doi:10.3389/fnut.2022.890316 PubMed
  9. [9] Jan de Vries et al.. Nutrients. 2019. Effects of β-Fructans Fiber on Bowel Function: A Systematic Review and Meta-Analysis. doi:10.3390/nu11010091 PubMed
  10. [10] Daniela da Silva Souza et al.. Nutrients. 2018. Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation. doi:10.3390/nu10111602 PubMed
  11. [11] Johnson W McRorie et al.. J Acad Nutr Diet. 2017. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and … doi:10.1016/j.jand.2016.09.021 PubMed
  12. [12] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
  13. [13] Shinji Jinno et al.. Nutrients. 2017. Maternal Prebiotic Ingestion Increased the Number of Fecal Bifidobacteria in Pregnant Women but Not in Their Neonates Aged One Month. doi:10.3390/nu9030196 PubMed
  14. [14] Annelisa Silva E Alves de Carvalho Santos et al.. Clin Nutr. 2017. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. doi:10.1016/j.clnu.2016.06.005 PubMed
  15. [15] Kulwara Meksawan et al.. Perit Dial Int. 2016. Effects of Fructo-Oligosaccharide Supplementation on Constipation in Elderly Continuous Ambulatory Peritoneal Dialysis Patients. doi:10.3747/pdi.2014.00015 PubMed
  16. [16] Petra A M J Scholtens et al.. World J Gastroenterol. 2014. Stool characteristics of infants receiving short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides: a review. doi:10.3748/wjg.v20.i37.13446 PubMed
  17. [17] Dan L Waitzberg et al.. Clin Nutr. 2013. Effect of synbiotic in constipated adult women - a randomized, double-blind, placebo-controlled study of clinical response. doi:10.1016/j.clnu.2012.08.010 PubMed
  18. [18] Chi-Hua Yen et al.. Nutrition. 2011. Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents--a placebo-controlled, diet-controlled trial. doi:10.1016/j.nut.2010.02.009 PubMed
  19. [19] Esther Nova et al.. J Med Food. 2011. Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults. doi:10.1089/jmf.2008.0328 PubMed
  20. [20] M Sabater-Molina et al.. J Physiol Biochem. 2009. Dietary fructooligosaccharides and potential benefits on health. doi:10.1007/BF03180584 PubMed
  21. [21] Syed H Tariq. J Am Med Dir Assoc. 2007. Constipation in long-term care. doi:10.1016/j.jamda.2007.02.009 PubMed
  22. [22] Takahisa Tokunaga. Biofactors. 2004. Novel physiological function of fructooligosaccharides. doi:10.1002/biof.552210117 PubMed
  23. [23] Nancy Moore et al.. Br J Nutr. 2003. Effects of fructo-oligosaccharide-supplemented infant cereal: a double-blind, randomized trial. doi:10.1079/bjn2003950 PubMed
  24. [24] D B Cockram et al.. J Ren Nutr. 1998. Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. doi:10.1016/s1051-2276(98)90034-6 PubMed

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.